Insurance increasingly dropping weight loss drugs like Wegovy, Zepbound
Insurance companies are increasingly dropping coverage for weight loss drugs like Wegovy and Zepbound due to rising costs, pushing patients to purchase through telehealth providers or manufacturers. Hims partners with Wegovy to offer the drug directly, while CVS expands coverage for Eli Lilly's anti-obesity pill and reinstates Zepbound later this year.
Mentioned
Related Signal
Adjacent reporting
- Some U.S. employers are dropping weight loss drug coverage as use surges
- US states drop Medicaid coverage of GLP-1 weight-loss drugs as demand rises
- STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more
- STAT+: Pharmalittle: We’re reading about Medicare and obesity drugs, Germany’s pricing plans, and more
- Hims Sales Miss on Rising Competition for Weight-Loss Drugs